Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy ...

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced positive topline results from its Phase 3 Casppian clinical trial evaluating the efficacy and safety of FP-001 42 mg (leuprolide ...